$SMMT
Summit Therapeutics Inc.

2021 Q2 Form 10-Q Financial Statement

#000159929821000027 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q4 2020 Q2
Revenue $57.00K $185.0K $170.0K
YoY Change -66.47% 54.17% 8.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.984M $5.802M $5.774M
YoY Change 3.64% 32.77% 247.83%
% of Gross Profit
Research & Development $23.92M $12.30M $13.57M
YoY Change 76.27% 70.36% 20.56%
% of Gross Profit
Depreciation & Amortization $347.0K $458.0K $347.0K
YoY Change 0.0% 27.22% -0.86%
% of Gross Profit
Operating Expenses $29.91M $13.73M $19.35M
YoY Change 54.59% 75.63% 44.45%
Operating Profit -$23.73M -$15.36M
YoY Change 54.53% 127.73%
Interest Expense $216.0K $54.00K -$55.00K
YoY Change -492.73% -190.0% -30.38%
% of Operating Profit
Other Income/Expense, Net -$686.0K -$67.00K -$114.0K
YoY Change 501.75%
Pretax Income -$24.42M -$13.56M -$15.47M
YoY Change 57.83% 74.77% 126.77%
Income Tax $0.00 -$120.0K -$191.0K
% Of Pretax Income
Net Earnings -$24.42M -$13.44M -$15.28M
YoY Change 59.8% 91.21% 128.62%
Net Earnings / Revenue -42835.09% -7265.95% -8987.65%
Basic Earnings Per Share -$0.27 -$0.23
Diluted Earnings Per Share -$0.27 -$175.9K -$0.23
COMMON SHARES
Basic Shares Outstanding 92.07M shares 82.26M shares 67.23M shares
Diluted Shares Outstanding 92.07M shares 67.23M shares

Balance Sheet

Concept 2021 Q2 2020 Q4 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.4M $66.42M $36.41M
YoY Change 183.95% 388.36% 68.02%
Cash & Equivalents $103.4M $66.42M $36.40M
Short-Term Investments
Other Short-Term Assets $963.0K $1.523M $1.260M
YoY Change -23.57% 8.86%
Inventory
Prepaid Expenses $5.727M $9.547M $8.546M
Receivables $1.053M $331.0K $464.0K
Other Receivables $10.35M $9.856M $8.872M
Total Short-Term Assets $121.5M $87.67M $55.55M
YoY Change 118.68% 10.1% 81.25%
LONG-TERM ASSETS
Property, Plant & Equipment $757.0K $725.0K $562.0K
YoY Change 34.7% 39.96% -46.98%
Goodwill $2.057M $2.030M $2.236M
YoY Change -8.01% 3.52%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $24.04M $14.82M $15.40M
YoY Change 56.1% -10.81% 48.05%
TOTAL ASSETS
Total Short-Term Assets $121.5M $87.67M $55.55M
Total Long-Term Assets $24.04M $14.82M $15.40M
Total Assets $145.5M $102.5M $70.95M
YoY Change 105.1% 6.49% 72.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.949M $6.140M $3.091M
YoY Change 124.81% 37.33% -40.21%
Accrued Expenses $6.132M $3.278M $4.518M
YoY Change 35.72% -42.88%
Deferred Revenue $7.140M $8.370M
YoY Change 220.08%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.89M $19.89M $13.20M
YoY Change 65.83% 44.48% 69.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $2.689M $2.511M $2.656M
YoY Change 1.24% -7.1% 32.8%
Total Long-Term Liabilities $2.689M $2.511M $2.656M
YoY Change 1.24% -7.1% 9.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.89M $19.89M $13.20M
Total Long-Term Liabilities $2.689M $2.511M $2.656M
Total Liabilities $26.09M $23.05M $19.00M
YoY Change 37.29% 32.56% 65.53%
SHAREHOLDERS EQUITY
Retained Earnings -$252.9M -$210.9M -$181.5M
YoY Change 39.34% 33.3%
Common Stock $974.0K $826.0K $672.0K
YoY Change 44.94% 22.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $119.4M $79.45M $53.60M
YoY Change
Total Liabilities & Shareholders Equity $145.5M $102.5M $70.95M
YoY Change 105.1% 6.49% 72.84%

Cashflow Statement

Concept 2021 Q2 2020 Q4 2020 Q2
OPERATING ACTIVITIES
Net Income -$24.42M -$13.44M -$15.28M
YoY Change 59.8% 91.21% 128.62%
Depreciation, Depletion And Amortization $347.0K $458.0K $347.0K
YoY Change 0.0% 27.22% -0.86%
Cash From Operating Activities -$19.17M -$7.971M -$16.79M
YoY Change 14.19% 26.93% -1299.36%
INVESTING ACTIVITIES
Capital Expenditures -$151.0K -$50.00K -$177.0K
YoY Change -14.69% 400.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$151.0K -$50.00K -$177.0K
YoY Change -14.69% 400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.08M 50.55M 53.00K
YoY Change 37790.57% -56264.44% -158.89%
NET CHANGE
Cash From Operating Activities -19.17M -7.971M -16.79M
Cash From Investing Activities -151.0K -50.00K -177.0K
Cash From Financing Activities 20.08M 50.55M 53.00K
Net Change In Cash 757.0K 42.53M -16.92M
YoY Change -104.48% -766.57% -1391.22%
FREE CASH FLOW
Cash From Operating Activities -$19.17M -$7.971M -$16.79M
Capital Expenditures -$151.0K -$50.00K -$177.0K
Free Cash Flow -$19.02M -$7.921M -$16.61M
YoY Change 14.5% 26.33% -1286.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001599298
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2
dei Entity Shell Company
EntityShellCompany
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36866
dei Entity Registrant Name
EntityRegistrantName
Summit Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1979717
dei Entity Address Address Line1
EntityAddressAddressLine1
One Broadway, 14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
514-7149
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
SMMT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
97381774 shares
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103386000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66417000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1053000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
331000 USD
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5727000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9547000 USD
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
963000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1523000 USD
CY2021Q2 smmt Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
10353000 USD
CY2020Q4 smmt Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
9856000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
121482000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
87674000 USD
CY2021Q2 smmt Research And Development Tax Credit Receivable Noncurrent
ResearchAndDevelopmentTaxCreditReceivableNoncurrent
7848000 USD
CY2020Q4 smmt Research And Development Tax Credit Receivable Noncurrent
ResearchAndDevelopmentTaxCreditReceivableNoncurrent
0 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
757000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
725000 USD
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7140000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2212000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
554000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
2057000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
2030000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11161000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11515000 USD
CY2021Q2 us-gaap Assets
Assets
145517000 USD
CY2020Q4 us-gaap Assets
Assets
102498000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6949000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6140000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6132000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4261000 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
661000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
729000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1006000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
390000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8370000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21888000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19890000 USD
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
365000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
569000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1148000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
75000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2689000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2511000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
26090000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
23045000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97351799 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97351799 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82575064 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82575064 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
974000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
826000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
373882000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
293367000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2579000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3794000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252850000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210946000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119427000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
79453000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
145517000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102498000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
170000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
249000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
494000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23923000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13572000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42302000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26484000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5984000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5774000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10169000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9346000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
29907000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
19346000 USD
us-gaap Operating Expenses
OperatingExpenses
52471000 USD
us-gaap Operating Expenses
OperatingExpenses
35830000 USD
CY2021Q2 us-gaap Other Operating Income
OtherOperatingIncome
6120000 USD
CY2020Q2 us-gaap Other Operating Income
OtherOperatingIncome
3820000 USD
us-gaap Other Operating Income
OtherOperatingIncome
11569000 USD
us-gaap Other Operating Income
OtherOperatingIncome
10640000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23730000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15356000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-40653000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-24696000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-686000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-114000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1251000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3147000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24416000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15470000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41904000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21549000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-191000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-136000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-24416000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15279000 USD
us-gaap Net Income Loss
NetIncomeLoss
-41904000 USD
us-gaap Net Income Loss
NetIncomeLoss
-21413000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90650854 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90650854 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67231900 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67231900 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86755983 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86755983 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67224799 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67224799 shares
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
540000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-52000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1215000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4676000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23876000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15331000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40689000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26089000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
64405000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
118000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74882000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
241000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3672000 USD
CY2021Q2 smmt Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party
AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
103000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
540000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-24416000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119427000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
79453000 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
118000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74882000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1138000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4540000 USD
smmt Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party
AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
103000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1215000 USD
us-gaap Net Income Loss
NetIncomeLoss
-41904000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119427000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
68405000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
530000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-52000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15279000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
53604000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
78863000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
827000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4676000 USD
us-gaap Net Income Loss
NetIncomeLoss
-21413000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
53604000 USD
us-gaap Net Income Loss
NetIncomeLoss
-41904000 USD
us-gaap Net Income Loss
NetIncomeLoss
-21413000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-100000 USD
smmt Interest Expense Noncash
InterestExpenseNoncash
315000 USD
smmt Interest Expense Noncash
InterestExpenseNoncash
120000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1495000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
292000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
470000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
187000 USD
us-gaap Depreciation
Depreciation
170000 USD
us-gaap Depreciation
Depreciation
175000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
512000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
522000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4540000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
827000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
704000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-41000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3968000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
348000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-195000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-54000 USD
smmt Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
7854000 USD
smmt Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
4463000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1554000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3083000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
672000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1111000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3277000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-548000 USD
smmt Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-451000 USD
smmt Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-225000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39843000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23491000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
190000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
159000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
168000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-190000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-327000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75000000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
105000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
110000000 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
54000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
110000000 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1138000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75979000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1023000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3617000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36969000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27432000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66417000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63842000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103386000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36410000 USD
us-gaap Interest Paid Net
InterestPaidNet
85000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
9000 USD
smmt Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
13000 USD
smmt Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2124000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Nature Of Operations
NatureOfOperations
Nature of the business and operations <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit Therapeutics Inc. and its consolidated subsidiaries ("Summit" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of novel antibiotics for serious infectious diseases. Summit is conducting a Phase 3 clinical program focused on the infectious disease C. difficile infection (or "CDI"). It is also seeking to expand the product candidate portfolio through the development of new mechanism, precision antibiotics using the proprietary Discuva Platform.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2020, Summit, a Delaware corporation, became the successor issuer to Summit Therapeutics plc, a public limited company incorporated under the laws of England and Wales with the Registrar of Companies of England and Wales, United Kingdom, for certain purposes under both the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such succession occurred pursuant to a statutory scheme of arrangement under U.K. law pursuant to which all Summit Therapeutics plc outstanding ordinary shares were exchanged on a five-for-one basis for newly issued shares of Summit common stock and Summit became the holding company of Summit Therapeutics plc (the predecessor registrant and former holding company) and its subsidiaries (which is referred to as the "Redomiciliation Transaction"). Concurrently, Summit Therapeutics plc was converted into a private limited company under the laws of England and Wales and renamed Summit Therapeutics Limited. In addition, the warrants and stock options to purchase shares of Summit Therapeutics plc were canceled and replacement warrants and stock options to purchase common stock in Summit Therapeutics Inc. were issued. The scheme of arrangement was accounted for as an exchange of equity interests among entities under common control. All assets and liabilities of Summit Therapeutics plc were assumed by Summit, resulting in the retention of the historical basis of accounting as if they had always been combined for accounting purposes and the historical consolidated financial statements of Summit Therapeutics plc became the historical consolidated financial statements of Summit Therapeutics Inc. All share and per share amounts for periods prior to the Redomiciliation Transaction in the financial statements were retroactively reflected to be presented as shares of our common stock, par value $0.01 per share.</span></div>
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div>
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103400000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252900000 USD
us-gaap Net Income Loss
NetIncomeLoss
-41900000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39800000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q2 us-gaap Number Of Countries In Which Entity Operates
NumberOfCountriesInWhichEntityOperates
2 segment
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
170000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
249000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
494000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
170000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
249000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
494000 USD
CY2021Q2 smmt Research And Development Credit Tax Rebate
ResearchAndDevelopmentCreditTaxRebate
4204000 USD
CY2020Q2 smmt Research And Development Credit Tax Rebate
ResearchAndDevelopmentCreditTaxRebate
2577000 USD
smmt Research And Development Credit Tax Rebate
ResearchAndDevelopmentCreditTaxRebate
7883000 USD
smmt Research And Development Credit Tax Rebate
ResearchAndDevelopmentCreditTaxRebate
4341000 USD
CY2021Q2 us-gaap Other Operating Income
OtherOperatingIncome
6120000 USD
CY2020Q2 us-gaap Other Operating Income
OtherOperatingIncome
3820000 USD
us-gaap Other Operating Income
OtherOperatingIncome
11569000 USD
us-gaap Other Operating Income
OtherOperatingIncome
10640000 USD
smmt Research And Development Credit Tax Rebate Small And Medium Enterprise
ResearchAndDevelopmentCreditTaxRebateSmallAndMediumEnterprise
7900000 USD
smmt Research And Development Credit Tax Rebate Small And Medium Enterprise
ResearchAndDevelopmentCreditTaxRebateSmallAndMediumEnterprise
4000000.0 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-24416000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15279000 USD
us-gaap Net Income Loss
NetIncomeLoss
-41904000 USD
us-gaap Net Income Loss
NetIncomeLoss
-21413000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90650854 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67231900 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86755983 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67224799 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90650854 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67231900 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86755983 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67224799 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12753983 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10884102 shares
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20444000 USD
CY2021Q2 smmt Finite Lived Intangible Assets Accumulated Amortization And Impairment
FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
9283000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11161000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20170000 USD
CY2020Q4 smmt Finite Lived Intangible Assets Accumulated Amortization And Impairment
FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
8655000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11515000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3672968 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2646350 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
649385 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.64
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
436836 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.60
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5233097 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.90
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
878568 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.51
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
18600000 USD
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4300000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3671000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
530000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4540000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
827000 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01

Files In Submission

Name View Source Status
0001599298-21-000027-index-headers.html Edgar Link pending
0001599298-21-000027-index.html Edgar Link pending
0001599298-21-000027.txt Edgar Link pending
0001599298-21-000027-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
smmt-20210630.htm Edgar Link pending
smmt-20210630.xsd Edgar Link pending
smmt-20210630_cal.xml Edgar Link unprocessable
smmt-20210630_def.xml Edgar Link unprocessable
smmt-20210630_htm.xml Edgar Link completed
smmt-20210630_lab.xml Edgar Link unprocessable
smmt-20210630_pre.xml Edgar Link unprocessable
sum-ex311_2021630x10q.htm Edgar Link pending
sum-ex321_2021630x10q.htm Edgar Link pending